<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Neurol</journal-id><journal-id journal-id-type="iso-abbrev">BMC Neurol</journal-id><journal-title-group><journal-title>BMC Neurology</journal-title></journal-title-group><issn pub-type="epub">1471-2377</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28525977</article-id><article-id pub-id-type="pmc">5437568</article-id><article-id pub-id-type="publisher-id">884</article-id><article-id pub-id-type="doi">10.1186/s12883-017-0884-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>The intracerebral hemorrhage acutely decreasing arterial pressure trial II (ICH ADAPT II) protocol</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gioia</surname><given-names>Laura</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Klahr</surname><given-names>Ana</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kate</surname><given-names>Mahesh</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Buck</surname><given-names>Brian</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Dowlatshahi</surname><given-names>Dariush</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Jeerakathil</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Emery</surname><given-names>Derek</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0590-7918</contrib-id><name><surname>Butcher</surname><given-names>Kenneth</given-names></name><address><phone>+1-780-248-1927</phone><email>ken.butcher@ualberta.ca</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.17089.37</institution-id><institution>Division of Neurology, </institution><institution>University of Alberta, </institution></institution-wrap>7th Floor Clinical Sciences Building, 11350-83rd Avenue, Edmonton, AB T6G 2B7 Canada </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2182 2255</institution-id><institution-id institution-id-type="GRID">grid.28046.38</institution-id><institution>Division of Neurology, </institution><institution>University of Ottawa, </institution></institution-wrap>Ottawa, ON Canada </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.17089.37</institution-id><institution>Department of Diagnostic Imaging, </institution><institution>University of Alberta, </institution></institution-wrap>Edmonton, AB Canada </aff></contrib-group><pub-date pub-type="epub"><day>19</day><month>5</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>19</day><month>5</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>17</volume><elocation-id>100</elocation-id><history><date date-type="received"><day>24</day><month>4</month><year>2017</year></date><date date-type="accepted"><day>10</day><month>5</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Aggressively lowering blood pressure (BP) in acute intracerebral hemorrhage (ICH) may improve outcome. Although there is no evidence that BP reduction changes cerebral blood flow, retrospective magnetic resonance imaging (MRI) studies have demonstrated sub-acute ischemic lesions in ICH patients. The primary aim of this study is to assess ischemic lesion development in patients randomized to two different BP treatment strategies. We hypothesize aggressive BP reduction is not associated with ischemic injury after ICH.</p></sec><sec><title>Methods</title><p>The <bold>I</bold>ntra<bold>c</bold>erebral <bold>H</bold>emorrhage <bold>A</bold>cutely <bold>D</bold>ecreasing <bold>B</bold>lood <bold>P</bold>ressure <bold>T</bold>rial II (ICH ADAPT II) is a phase II multi-centre randomized open-label, blinded-endpoint trial. Acute ICH patients (<italic>N</italic>&#x000a0;=&#x000a0;270) are randomized to a systolic blood pressure (SBP) target of &#x0003c;140 or &#x0003c;180&#x000a0;mmHg. Acute ICH patients within 6&#x000a0;h of onset and two SBP measurements &#x02265;140&#x000a0;mmHg recorded &#x0003e;2 mins apart qualify. SBP is managed with a pre-defined treatment protocol. Patients undergo MRI at 48&#x000a0;h, Days 7 and 30, with clinical assessment at Day 30 and 90. The primary outcome is diffusion weighted imaging (DWI) lesion frequency at 48&#x000a0;h. Secondary outcomes include cumulative DWI lesion rate frequency within 30&#x000a0;days, absolute hematoma growth, prediction of DWI lesion incidence, 30-day mortality rates, day 90 functional outcome, and cognitive status.</p></sec><sec><title>Discussion</title><p>This trial will assess the impact of hypertensive therapies on physiological markers of ischemic injury. The findings of this study will provide evidence for the link, or lack thereof, between BP reduction and ischemic injury in ICH patients.</p></sec><sec><title>Trial registration</title><p>This study is registered with <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">clinicaltrials.gov&#x000a0;</ext-link> (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02281838">NCT02281838</ext-link>, first received October 29, 2014).</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s12883-017-0884-4) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Blood Pressure</kwd><kwd>Intracerebral Hemorrhage</kwd><kwd>DWI</kwd><kwd>MRI</kwd><kwd>Stroke</kwd><kwd>Clinical Trial</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004411</institution-id><institution>Heart and Stroke Foundation of Canada</institution></institution-wrap></funding-source><award-id>GIA G-14-0006004</award-id><principal-award-recipient><name><surname>Butcher</surname><given-names>Kenneth</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Acute management of elevated blood pressure (BP) in acute intracerebral hemorrhage (ICH) remains an area of clinical equipoise. Phase III studies have failed to demonstrate marked improvements in clinical outcome when BP is lowered aggressively [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. The most recent trial demonstrated a trend to worse outcomes in patients in whom BP was lowered to 120&#x02013;140&#x000a0;mmHg [<xref ref-type="bibr" rid="CR2">2</xref>]. Although aggressive BP reduction has not been associated with lower cerebral perfusion [<xref ref-type="bibr" rid="CR3">3</xref>], magnetic resonance imaging (MRI) studies have reported acute and subacute ischemic lesions in 14&#x02013;41% of ICH patients [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>]. These lesions have been associated with aggressive BP treatment as well as unfavorable clinical outcomes but these data are all retrospective [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Therefore, we designed a prospective randomized study to definitively determine whether acute BP reduction is associated with an elevated risk of ischemic injury, detected with diffusion-weighted imaging (DWI).</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study design</title><p>The&#x000a0;<bold>I</bold>ntra<bold>c</bold>erebral <bold>H</bold>emorrhage <bold>A</bold>cutely&#x000a0;<bold>D</bold>ecreasing <bold>A</bold>rterial <bold>P</bold>ressure <bold>T</bold>rial II (ICH ADAPT II) is a phase II multi-center prospective, randomized, open-label study with blinded-evaluation (PROBE). Eligible ICH patients are randomized 1:1 to systolic BP (SBP) targets of &#x0003c;140 or &#x0003c;180&#x000a0;mmHg (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). This study is registered with <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">clinicaltrials.gov</ext-link> (NCT02281838). The primary study aim is to assess DWI lesion frequency in patients randomized to aggressive versus conservative BP targets.<fig id="Fig1"><label>Fig. 1</label><caption><p>Study Schema</p></caption><graphic xlink:href="12883_2017_884_Fig1_HTML" id="MO1"/></fig>
</p></sec><sec id="Sec4"><title>Patient population</title><p>
<bold><italic>Inclusion criteria</italic></bold>
<list list-type="bullet"><list-item><p>Patients &#x02265;18&#x000a0;years with spontaneous ICH &#x02264;6&#x000a0;h from onset</p></list-item><list-item><p>Two SBP measurements &#x02265;140&#x000a0;mmHg recorded &#x0003e;2&#x000a0;min apart</p></list-item><list-item><p>Hematoma volume on CT &#x0003c;90&#x000a0;mL, as estimated using the ABC/2 method [<xref ref-type="bibr" rid="CR10">10</xref>]</p></list-item><list-item><p>Onset &#x02264;6&#x000a0;h prior to randomization</p></list-item><list-item><p>Glasgow Coma Scale (GCS) &#x02265;5 prior to randomization</p></list-item></list>
</p><p>
<bold><italic>Exclusion criteria</italic></bold>
<list list-type="bullet"><list-item><p>Definite contraindication to BP reduction (i.e. severe arterial stenosis, MoyaMoya disease)</p></list-item><list-item><p>Definite indication for BP reduction (i.e. hypertensive encephalopathy or aortic dissection)</p></list-item><list-item><p>Contraindication to MRI (i.e. cardiac pacemaker)</p></list-item><list-item><p>Suspected secondary cause of ICH</p></list-item><list-item><p>Ischemic stroke &#x0003c;90&#x000a0;days</p></list-item><list-item><p>Planned hematoma resection</p></list-item><list-item><p>Pre-morbid modified Rankin score (mRS) &#x02265;3</p></list-item><list-item><p>Life expectancy &#x0003c;6&#x000a0;months</p></list-item><list-item><p>Early implementation of palliative care</p></list-item></list>
</p></sec><sec id="Sec5"><title>Randomization</title><p>All patients undergo standard screening assessments including BP, GCS, and National Institutes of Health Stroke Scale (NIHSS) scores prior to randomization (Table <xref rid="Tab1" ref-type="table">1</xref>). A centralized web-based randomization process is used to assign BP treatment target.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Summary of trial procedures</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Screening/Randomization</th><th>24&#x000a0;&#x000b1;&#x000a0;3&#x000a0;h</th><th>48&#x000a0;&#x000b1;&#x000a0;12&#x000a0;h</th><th>Day 7&#x000a0;&#x000b1;&#x000a0;2</th><th>Day 30&#x000a0;&#x000b1;&#x000a0;5</th><th>Day 90&#x000a0;&#x000b1;&#x000a0;30</th></tr></thead><tbody><tr><td>Eligibility Criteria</td><td>&#x025a1;</td><td/><td/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>Signed Informed Consent</td><td>&#x025a1;</td><td/><td/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>Past Medical History</td><td>&#x025a1;</td><td/><td/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>Vital Signs (BP, HR) Monitoring</td><td>&#x025a1;</td><td>&#x025a1;</td><td>&#x025a1;</td><td>&#x025a1;</td><td>&#x025a1;</td><td>&#x025a1;</td></tr><tr><td>Medications</td><td>&#x025a1;</td><td/><td/><td>&#x025a1;</td><td>&#x025a1;</td><td>&#x025a1;</td></tr><tr><td>CT scan</td><td>&#x025a1;</td><td>&#x025a1;</td><td/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>MRI scan</td><td align="center"/><td/><td>&#x025a1;</td><td>&#x025a1;</td><td>&#x025a1;</td><td align="center"/></tr><tr><td>NIHSS</td><td>&#x025a1;</td><td>&#x025a1;</td><td>&#x025a1;</td><td>&#x025a1;</td><td>&#x025a1;</td><td>&#x025a1;</td></tr><tr><td>Glasgow Coma Scale</td><td>&#x025a1;</td><td>&#x025a1;</td><td>&#x025a1;</td><td>&#x025a1;</td><td>&#x025a1;</td><td>&#x025a1;</td></tr><tr><td>Modified Rankin Scale</td><td>&#x025a1;</td><td/><td/><td>&#x025a1;</td><td>&#x025a1;</td><td>&#x025a1;</td></tr><tr><td>Montreal Cognitive Assessment</td><td>&#x025a1;</td><td/><td/><td>&#x025a1;</td><td>&#x025a1;</td><td>&#x025a1;</td></tr><tr><td>Barthel Index, EuroQOL</td><td align="center"/><td/><td/><td align="center"/><td>&#x025a1;</td><td>&#x025a1;</td></tr><tr><td>AE/SAE Reporting</td><td align="center"/><td>&#x025a1;</td><td>&#x025a1;</td><td>&#x025a1;</td><td>&#x025a1;</td><td>&#x025a1;</td></tr><tr><td>End of Study Report</td><td align="center"/><td/><td/><td align="center"/><td align="center"/><td>&#x025a1;</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec6"><title>Interventions</title><sec id="Sec7"><title>BP Management</title><p>The assigned BP target is achieved and maintained using an intravenous antihypertensive drug bolus protocol (Table <xref rid="Tab2" ref-type="table">2</xref>). Patients in the aggressive BP target (SBP &#x0003c;140&#x000a0;mmHg) group immediately receive a 10&#x000a0;mg intravenous (IV) bolus of labetalol, followed by repeated boluses designed to lower systolic BP to &#x0003c;140&#x000a0;mmHg within 60&#x000a0;min of randomization. The protocol utilizes IV enalapril and hydralazine boluses as well.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Acute BP treatment protocols</p></caption><table frame="hsides" rules="groups"><tbody><tr><td colspan="2">A. &#x0003c;140&#x000a0;mmHg Target Group</td></tr><tr><td/><td>Target SBP &#x0003c;140&#x000a0;mmHg within 30&#x000a0;min of randomization</td></tr><tr><td>Monitoring</td><td>&#x025cf; Record BP/HR q<sup>a</sup>5 min during active treatment; q15 min&#x000a0;&#x000d7;&#x000a0;1&#x000a0;h, q30 min&#x000a0;&#x000d7;&#x000a0;5&#x000a0;h and q1h&#x000a0;&#x000d7;&#x000a0;18&#x000a0;h</td></tr><tr><td>Labetalol (IV)</td><td>&#x025cf; Labetalol test dose: 10&#x000a0;mg bolus over 1&#x000a0;min<break/>&#x025cf; If SBP &#x02265;140&#x000a0;mmHg and HR &#x0003e;55 BPM, repeat 10&#x000a0;mg bolus in 5&#x000a0;min.<break/>&#x025cf; 10&#x02013;20&#x000a0;mg IV push q5 min until SBP &#x0003c;140&#x000a0;mmHg or HR &#x0003c;55 BPM<break/>&#x025cf; Maximum labetalol dose: 300&#x000a0;mg/24&#x000a0;h</td></tr><tr><td>And Enalapril (IV) (If available)</td><td>&#x025cf; Enalapril 1.25&#x000a0;mg bolus</td></tr><tr><td>And/or Hydralazine (IV)</td><td>If BP persistently &#x0003e;140&#x000a0;mmHg:<break/>&#x025cf; Hydralazine test dose: 5&#x000a0;mg IV bolus over 1&#x000a0;min<break/>&#x025cf; If SBP &#x02265;140&#x000a0;mmHg, repeat 5&#x000a0;mg IV bolus in 5&#x000a0;min<break/>&#x025cf; 10&#x02013;20&#x000a0;mg IV bolus q5 min until SBP &#x0003c;140&#x000a0;mmHg<break/>&#x025cf; Maximum hydralazine dose&#x000a0;=&#x000a0;240&#x000a0;mg/24&#x000a0;h</td></tr><tr><td>Continuous IV Infusions (ICU admission)</td><td>If BP persistently &#x0003e;140&#x000a0;mmHg:<break/>&#x025cf; Labetalol infusion 2&#x02013;8&#x000a0;mg/min (maximum 300&#x000a0;mg/24&#x000a0;h) and/or hydralazine infusion 50&#x02013;150&#x000a0;&#x003bc;g/min</td></tr><tr><td colspan="2">Maintenance Therapy</td></tr><tr><td colspan="2">Maintain SBP &#x0003c;140&#x000a0;mmHg &#x000d7; 24&#x000a0;h minimum</td></tr><tr><td>IV treatment prn<sup>b</sup>
</td><td>If SBP &#x0003e;140&#x000a0;mmHg at any point:<break/>&#x025cf; Labetalol (10&#x02013;20&#x000a0;mg) / hydralazine (10&#x02013;20&#x000a0;mg) boluses. Record BP/HR 5 and 15&#x000a0;min later<break/>&#x025cf; Enalapril 1.25&#x000a0;mg q6 h if SBP &#x0003e;140&#x000a0;mmHg<break/>&#x025cf; If SBP &#x02264;135&#x000a0;mmHg or HR &#x0003c;55 BPM, hold maintenance dose</td></tr><tr><td colspan="2">B. &#x0003c;180&#x000a0;mmHg Target Group</td></tr><tr><td/><td>Protocol to be used <underline>only</underline> if SBP &#x02265;180&#x000a0;mmHg</td></tr><tr><td>Monitoring</td><td>&#x025cf; as listed above</td></tr><tr><td>Labetalol (IV)</td><td>&#x025cf; Labetalol test dose: 10&#x000a0;mg bolus over 1&#x000a0;min<break/>&#x025cf; If SBP &#x02265;180&#x000a0;mmHg and HR &#x0003e;55 BPM, repeat 10&#x000a0;mg bolus in 5&#x000a0;min.<break/>&#x025cf; 10&#x02013;20&#x000a0;mg IV push q5 min until SBP &#x0003c;180&#x000a0;mmHg or HR &#x0003c;55 BPM<break/>&#x025cf; Maximum labetalol dose: 300&#x000a0;mg/24&#x000a0;h</td></tr><tr><td>Hydralazine (IV)</td><td>If BP persistently &#x0003e;180&#x000a0;mmHg:<break/>&#x025cf; Hydralazine test dose: 5&#x000a0;mg IV bolus over 1&#x000a0;min<break/>&#x025cf; If SBP &#x02265;180&#x000a0;mmHg, repeat 5&#x000a0;mg IV bolus in 5&#x000a0;min<break/>&#x025cf; 10&#x02013;20&#x000a0;mg IV bolus q5 min until SBP &#x0003c;180&#x000a0;mmHg<break/>&#x025cf; Maximum hydralazine dose&#x000a0;=&#x000a0;240&#x000a0;mg/24&#x000a0;h</td></tr><tr><td colspan="2">Maintenance Therapy</td></tr><tr><td>IV treatment prn</td><td>If SBP &#x0003e;180&#x000a0;mmHg at any point during 24&#x000a0;h:<break/>&#x025cf; Labetalol (10&#x02013;20&#x000a0;mg) / hydralazine (10&#x02013;20&#x000a0;mg) boluses. Record BP/HR 5 and 15&#x000a0;min later</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>q&#x000a0;=&#x000a0;every, <sup>b</sup>prn&#x000a0;=&#x000a0;when necessary</p></table-wrap-foot></table-wrap>
</p><p>Patients randomized to the conservative arm (SBP &#x0003c;180&#x000a0;mmHg group) are treated with antihypertensive agents only if SBP &#x02265;180&#x000a0;mmHg. BP and heart rate (HR) are continuously monitored non-invasively for the first 24&#x000a0;h.</p></sec></sec><sec id="Sec8"><title>Imaging Procedures</title><p>
<italic>Baseline:</italic> Diagnostic non-contrast computed tomography (CT) scan<italic>.</italic> This consists of 5&#x000a0;mm slices, no gap (120 kvp, 300&#x000a0;mA per slice) through the entire brain (l8&#x02013;20 slices with a 512&#x000a0;&#x000d7;&#x000a0;512 matrix).</p><p>
<italic>24-h:</italic> Repeat CT scan at 24&#x000a0;&#x000b1;&#x000a0;3&#x000a0;h to assess for hematoma expansion and peri-hematoma edema volume.</p><p>
<italic>48-h:</italic> MRI at 48&#x000a0;&#x000b1;&#x000a0;12&#x000a0;h, including a T1-weighted sagittal localizer, T2-weighted images, DWI (the primary endpoint), Fluid-attenuated Inverse Recovery (FLAIR), Susceptibility Weighted Imaging (SWI), and pulse Arterial Spin Labeling (ASL; optional sequence). DWI sequences are combined to form isotropic (trace) diffusion images and Apparent Diffusion Coefficient (ADC) maps are generated from these raw data. ADC maps are used to ensure all lesions represent true diffusion restriction and not T2 shine through effects. FLAIR sequences are also utilized to assess chronic small vessel ischemic changes. SWI sequences are used to assess the burden (number, total volume and topography) of cerebral microbleeds. Pulse ASL data is used to generate blood flow maps to determine if DWI lesions are correlated with hypoperfusion. All image analyses are completed centrally by raters blinded to BP treatment group allocation.</p><p>
<italic>Days 7 and 30:</italic> MRI repeat at Days 7&#x000a0;&#x000b1;&#x000a0;2 and 30&#x000a0;&#x000b1;&#x000a0;5 to assess for new DWI lesion development and evolution of those previously identified.</p></sec><sec id="Sec9"><title>Clinical assessments</title><p>In-hospital clinical assessments (24&#x000a0;h, 48&#x000a0;h, day 7 and hospital discharge) of neurological deterioration are performed using GCS and NIHSS. Discharge mRS scores is obtained to assess disability and Montreal Cognitive Assessment (MoCA) to determine cognitive changes. This latter assessment is relevant as development of DWI lesions may impair cognition in ICH patients. All neurological, disability, and cognitive assessments are repeated at days 30 and 90.</p></sec><sec id="Sec10"><title>Primary outcome</title><p>The primary endpoint is DWI lesion frequency on the 48-h MRI, which is the time point DWI lesions have most commonly been observed after ICH [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>]. This is also the time point most relevant to acute BP reduction.</p><p>
<bold>Secondary outcomes</bold>
<list list-type="bullet"><list-item><p>Hematoma growth at 24&#x000a0;h<list list-type="bullet"><list-item><p>
<italic>Hypothesi</italic>s: The mean hematoma growth will be smaller in the SBP &#x0003c;140&#x000a0;mmHg group.</p></list-item></list>
</p></list-item><list-item><p>Cumulative DWI lesion rate frequency within 30&#x000a0;days<list list-type="bullet"><list-item><p>
<italic>Hypothesis:</italic> The rate of DWI lesion development will be higher in the SBP &#x0003c;140&#x000a0;mmHg group.</p></list-item></list>
</p></list-item><list-item><p>Day 30 mortality rates<list list-type="bullet"><list-item><p>
<italic>Hypothesis:</italic> DWI lesion development will predict mortality, which should be independent of BP randomization.</p></list-item></list>
</p></list-item><list-item><p>Day 90 mRS scores<list list-type="bullet"><list-item><p>
<italic>Hypothesis:</italic> Median mRS will be positively correlated with number of DWI lesions.</p></list-item></list>
</p></list-item><list-item><p>Day 90 MoCA<list list-type="bullet"><list-item><p>
<italic>Hypothesis:</italic> MoCA scores will be lower in patients with DWI lesions.</p></list-item></list>
</p></list-item></list>
</p></sec><sec id="Sec11"><title>Data safety monitoring body (DSMB)</title><p>The DSMB (Additional file <xref rid="MOESM1" ref-type="media">1</xref>) reviews the proportion of patients with neurological deterioration within 48&#x000a0;h (defined as an increase in NIHSS &#x02265;4 points), 90-day mortality and all serious adverse events (SAE) after 33% and 67% of patients are enrolled. The committee may modify or stop the trial at any point.</p></sec><sec id="Sec12"><title>Sample size estimates</title><p>The sample size is based on an observed DWI lesion frequency of 26% in the &#x0003c;180&#x000a0;mmHg target group [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>]. The odds ratio for DWI lesion occurrence is 1.03 per decrease in mmHg of mean arterial pressure (MAP) between baseline and the MRI scan [<xref ref-type="bibr" rid="CR5">5</xref>]. In ICH ADAPT I, MAP in the aggressive treatment group decreased by an average of 28&#x000a0;mmHg at the time of the primary endpoint assessment. Assuming a similar treatment effect in ICH ADAPT II, the predicted effect of SBP reduction &#x0003c;140&#x000a0;mmHg is an odds ratio of DWI lesion incidence of 1.84. The trial has been powered to detect a 0.84 (relative) increase in the frequency of DWI lesions in the &#x0003c;140&#x000a0;mmHg target group. The predicted absolute increase in the proportion of patients with DWI lesions is 22%.</p><p>
<italic>Hypotheses:</italic>
<list list-type="bullet"><list-item><p>H<sub>0</sub>: The proportion of patients with DWI lesions in the&#x000a0;&#x0003c;&#x000a0;140&#x000a0;mmHg treatment arm will be&#x000a0;&#x02264;&#x000a0;0.48.</p></list-item><list-item><p>H<sub>A</sub>: The proportion of patients with DWI lesions in the&#x000a0;&#x0003c;&#x000a0;140&#x000a0;mmHg treatment arm will be&#x000a0;&#x0003e;&#x000a0;0.48.</p><p>The primary analysis will be a one-sided test of proportions at the alpha&#x000a0;=&#x000a0;0.025 level. A sample size of 180 evaluable patients will be required to reject the null hypothesis with 80% power (alpha&#x000a0;=&#x000a0;0.025). To account for withdrawal of consent and missing data related to early death and MRI contraindications, the sample size has been increased to 270 patients.</p></list-item></list>
</p></sec><sec id="Sec13"><title>Statistical analyses</title><p>The primary endpoint will be tested using Fisher&#x02019;s Exact test. There will be no interim analyses for efficacy or futility.</p></sec></sec><sec id="Sec14"><title>Discussion</title><p>Elevated BP has been associated with hematoma growth, mortality, and disability after ICH [<xref ref-type="bibr" rid="CR11">11</xref>]. However, the most recent clinical trial data have revived concerns about the safety of very aggressive BP reduction [<xref ref-type="bibr" rid="CR2">2</xref>]. It is unknown if this trend to worse outcome is related to cerebral ischemic changes, but it is one possible mechanism [<xref ref-type="bibr" rid="CR12">12</xref>]. There are mixed data regarding the development of ischemic lesions after ICH and its association with BP. Retrospective studies have suggested that there is a negative, positive, and even no correlation between the two [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>].</p><p>The current trial utilizes a physiological endpoint that is more sensitive to ischemic injury to determine whether aggressive BP reduction in ICH patients exacerbates DWI lesion development, in individual patients. We have previously conducted a trial, ICH ADAPT I, in which ICH patients were randomized to aggressive (SBP &#x0003c;150&#x000a0;mmHg) versus conservative (SBP &#x0003c;180&#x000a0;mmHg) BP management strategies [<xref ref-type="bibr" rid="CR3">3</xref>]. We did not find a difference in peri-hematoma cerebral blood flow (CBF) in these two groups. Most importantly, the magnitude of BP change was not related to regional CBF [<xref ref-type="bibr" rid="CR3">3</xref>]. In contrast, several studies indicate that delayed cerebral ischemia, evident on MRI scan only, is common within the first week after ICH [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>]. Although the majority of peri-hematoma DWI hyperintensities result from plasma derived edema,[<xref ref-type="bibr" rid="CR15">15</xref>] true diffusion restriction representing bioenergetic compromise in this region and topographically remote areas are also present in some patients [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>]. These DWI lesions tend to be small but are still a subject of concern as longitudinal studies indicate the probability of death/dependence at one year is increased between five and six-fold in these patients [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR16">16</xref>].</p><p>Canadian Stroke Best Practices recommendations for hyperacute stroke care recognize the safety of aggressively reducing SBP [<xref ref-type="bibr" rid="CR17">17</xref>]. Furthermore, current American Heart Association/American Stroke Association guidelines advise lowering SBP &#x0003c;140&#x000a0;mmHg given its potential to improve patient prognosis in ICH patients, but more aggressive treatment is not encouraged [<xref ref-type="bibr" rid="CR18">18</xref>]. These recommendations are based primarily on the results of two phase III studies which have failed to demonstrate an increase in the proportion of patients with good clinical outcomes when BP is lowered aggressively [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. In the Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT II), 2839 ICH patients were randomized within 6&#x000a0;h of symptom onset to a SBP target of &#x0003c;140 or &#x0003c;180&#x000a0;mmHg. The rate of death/disability was similar in the &#x0003c;140&#x000a0;mmHg target group (52%) and the &#x0003c;180&#x000a0;mmHg target group (55.3%; odds ratio with intensive treatment, 0.87; 95% CI, 0.75 to 1.01; <italic>p</italic>&#x000a0;=&#x000a0;0.06) [<xref ref-type="bibr" rid="CR1">1</xref>]. In the Antihypertensive Treatment of Acute Cerebral Hemorrhage II (ATACH II), patients were randomized earlier (4.5 rather than 6&#x000a0;h after symptom onset) to the aggressive and conservative BP strategies [<xref ref-type="bibr" rid="CR2">2</xref>]. This trial recruited 1000 ICH patients, in which the primary outcome of death and disability (GCS &#x0003e;5) was observed in 38.7% vs. 37.7% in the aggressive vs. conservative treatment, respectively. The investigators concluded that aggressive antihypertensive therapy did not improve outcome.</p><p>At this point the optimal BP treatment strategy remains unknown. It has been hypothesized that an earlier intervention (e.g., in the prehospital setting) may be needed to improve patient prognosis, and small clinical trials have demonstrated the feasibility and safety of hyperacute BP management in stroke patients [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. However, it may be that in some patients aggressive BP reduction precipitate and/or exacerbate ischemic lesion development. This can only be addressed with a randomized controlled trial specifically addressing this endpoint.</p><p>In conclusion, ICH ADAPT II will provide evidence for the link, or lack thereof, between BP reduction and ischemic injury. This will add support for the safety of early systolic BP reduction to &#x0003c;140&#x000a0;mmHg, or alternatively a more nuanced approach to acute hypertension management in ICH patients.</p></sec><sec sec-type="supplementary-material"><title>Additional files</title><sec id="Sec15"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12883_2017_884_MOESM1_ESM.doc"><label>Additional file 1:</label><caption><p>Data Safety Monitoring Body Members. (DOC 25 kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="12883_2017_884_MOESM2_ESM.doc"><label>Additional file 2:</label><caption><p>Participant Information Sheet and Consent Form. (DOC 51 kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="12883_2017_884_MOESM3_ESM.doc"><label>Additional file 3:</label><caption><p>Deferred Consent for Research Participation. (DOC 29 kb)</p></caption></media></supplementary-material>
</p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ADC</term><def><p>Apparent diffusion coefficient</p></def></def-item><def-item><term>ASL</term><def><p>Arterial spin labeling</p></def></def-item><def-item><term>ATACH II</term><def><p>Antihypertensive treatment of acute cerebral hemorrhage II</p></def></def-item><def-item><term>BP</term><def><p>Blood pressure</p></def></def-item><def-item><term>CBF</term><def><p>Cerebral blood flow</p></def></def-item><def-item><term>CT</term><def><p>Computed tomography</p></def></def-item><def-item><term>DSMB</term><def><p>Data safety monitoring body</p></def></def-item><def-item><term>DWI</term><def><p>Diffusion-weighted imaging</p></def></def-item><def-item><term>FLAIR</term><def><p>Fluid-attenuated inverse recovery</p></def></def-item><def-item><term>GCS</term><def><p>Glasgow coma scale</p></def></def-item><def-item><term>ICH ADAPT II</term><def><p>
<underline>I</underline>ntra<underline>c</underline>erebral <underline>H</underline>emorrhage <underline>A</underline>cutely <underline>D</underline>ecreasing Blood <underline>P</underline>ressure <underline>T</underline>rial II</p></def></def-item><def-item><term>ICH</term><def><p>Intracerebral hemorrhage</p></def></def-item><def-item><term>INTERACT II</term><def><p>Intensive blood pressure reduction in acute cerebral hemorrhage II</p></def></def-item><def-item><term>MAP</term><def><p>Mean arterial pressure</p></def></def-item><def-item><term>MoCA</term><def><p>Montreal cognitive assessment</p></def></def-item><def-item><term>MRI</term><def><p>Magnetic resonance imaging</p></def></def-item><def-item><term>mRS</term><def><p>Modified Rankin scale</p></def></def-item><def-item><term>NIHSS</term><def><p>National Institutes of Health Stroke Scale</p></def></def-item><def-item><term>PROBE</term><def><p>Prospective, randomized, open-label study with blinded-evaluation</p></def></def-item><def-item><term>SAE</term><def><p>Serious adverse events</p></def></def-item><def-item><term>SBP</term><def><p>Systolic blood pressure</p></def></def-item><def-item><term>SWI</term><def><p>Susceptibility Weighted Imaging</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Electronic supplementary material</bold></p><p>The online version of this article (doi:10.1186/s12883-017-0884-4) contains supplementary material, which is available to authorized users.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable.</p><sec id="FPar1"><title>Funding</title><p>The trial is funded by the Heart and Stroke Foundation of Canada (GIA G-14-0006004).</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p>Not applicable.</p></sec><sec id="FPar3"><title>Authors&#x02019; contributions</title><p>LG, AK, and KB drafted the manuscript. AK and KB will be involved in the main data analysis. LG, MK, BB, DD, TJ, DE, and KB are involved in data collection. KB designed the trial and wrote the protocol. All authors read and approved the final manuscript.</p></sec><sec id="FPar4"><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec id="FPar5"><title>Consent for publication</title><p>Not applicable.</p></sec><sec id="FPar6"><title>Ethics approval and consent to participate</title><p>This study is being conducted according to Canadian and international standards of Good Clinical Practice for all studies. Applicable government regulations and University of Alberta research policies and procedures are followed. This protocol and any amendments have been submitted and approved by the University of Alberta Health and Research Ethics Board. Informed consent (Additional file <xref rid="MOESM2" ref-type="media">2</xref>) is obtained from the patient, or substitute decision maker prior to randomization. A deferred consent (Additional file <xref rid="MOESM3" ref-type="media">3</xref>) procedure is used in cases where the patient is incapacitated and a surrogate decision maker is not immediately available to provide consent.</p></sec><sec id="FPar7"><title>Publisher&#x02019;s Note</title><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>CS</given-names></name><name><surname>Heeley</surname><given-names>E</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Stapf</surname><given-names>C</given-names></name><name><surname>Delcourt</surname><given-names>C</given-names></name><etal/></person-group><article-title>Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage</article-title><source>N Engl J Med</source><year>2013</year><volume>368</volume><fpage>2355</fpage><lpage>2365</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1214609</pub-id><pub-id pub-id-type="pmid">23713578</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qureshi</surname><given-names>AI</given-names></name><name><surname>Palesch</surname><given-names>YY</given-names></name><name><surname>Barsan</surname><given-names>WG</given-names></name><name><surname>Hanley</surname><given-names>DF</given-names></name><name><surname>Hsu</surname><given-names>CY</given-names></name><name><surname>Martin</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Intensive Blood-Pressure Lowering in Patients with Acute Cerebral Hemorrhage</article-title><source>N Engl J Med</source><year>2016</year><volume>375</volume><issue>11</issue><fpage>1033</fpage><lpage>1043</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1603460</pub-id><pub-id pub-id-type="pmid">27276234</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butcher</surname><given-names>KS</given-names></name><name><surname>Jeerakathil</surname><given-names>T</given-names></name><name><surname>Hill</surname><given-names>M</given-names></name><name><surname>Demchuk</surname><given-names>AM</given-names></name><name><surname>Dowlatshahi</surname><given-names>D</given-names></name><name><surname>Coutts</surname><given-names>SB</given-names></name><etal/></person-group><article-title>The intracerebral hemorrhage acutely decreasing arterial pressure trial</article-title><source>Stroke</source><year>2013</year><volume>44</volume><issue>3</issue><fpage>620</fpage><lpage>626</lpage><pub-id pub-id-type="doi">10.1161/STROKEAHA.111.000188</pub-id><pub-id pub-id-type="pmid">23391776</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prabhakaran</surname><given-names>S</given-names></name><name><surname>Gupta</surname><given-names>R</given-names></name><name><surname>Ouyang</surname><given-names>B</given-names></name><name><surname>John</surname><given-names>S</given-names></name><name><surname>Temes</surname><given-names>RE</given-names></name><name><surname>Mohammad</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Acute brain infarcts after spontaneous intracerebral hemorrhage: a diffusion-weighted imaging study</article-title><source>Stroke</source><year>2010</year><volume>41</volume><fpage>89</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1161/STROKEAHA.109.566257</pub-id><pub-id pub-id-type="pmid">19892994</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menon</surname><given-names>RS</given-names></name><name><surname>Burgess</surname><given-names>RE</given-names></name><name><surname>Wing</surname><given-names>JJ</given-names></name><name><surname>Gibbons</surname><given-names>MC</given-names></name><name><surname>Shara</surname><given-names>NM</given-names></name><name><surname>Fernandez</surname><given-names>S</given-names></name><etal/></person-group><article-title>Predictors of highly prevalent brain ischemia in intracerebral hemorrhage</article-title><source>Ann Neurol</source><year>2012</year><volume>71</volume><fpage>199</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1002/ana.22668</pub-id><pub-id pub-id-type="pmid">22367992</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>DW</given-names></name><name><surname>Han</surname><given-names>MK</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Yun</surname><given-names>SC</given-names></name><name><surname>Jeon</surname><given-names>SB</given-names></name><name><surname>Bae</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>New ischemic lesions coexisting with acute intracerebral hemorrhage</article-title><source>Neurology</source><year>2012</year><volume>79</volume><fpage>848</fpage><lpage>855</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3182648a79</pub-id><pub-id pub-id-type="pmid">22843271</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gregoire</surname><given-names>SM</given-names></name><name><surname>Charidimou</surname><given-names>A</given-names></name><name><surname>Gadapa</surname><given-names>N</given-names></name><name><surname>Dolan</surname><given-names>E</given-names></name><name><surname>Antoun</surname><given-names>N</given-names></name><name><surname>Peeters</surname><given-names>A</given-names></name><etal/></person-group><article-title>Acute ischaemic brain lesions in intracerebral haemorrhage: multicentre cross-sectional magnetic resonance imaging study</article-title><source>Brain</source><year>2011</year><volume>134</volume><fpage>2376</fpage><lpage>2386</lpage><pub-id pub-id-type="doi">10.1093/brain/awr172</pub-id><pub-id pub-id-type="pmid">21841203</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimberly</surname><given-names>WT</given-names></name><name><surname>Gilson</surname><given-names>A</given-names></name><name><surname>Rost</surname><given-names>NS</given-names></name><name><surname>Rosand</surname><given-names>J</given-names></name><name><surname>Viswanathan</surname><given-names>A</given-names></name><name><surname>Smith</surname><given-names>EE</given-names></name><etal/></person-group><article-title>Silent ischemic infarcts are associated with hemorrhage burden in cerebral amyloid angiopathy</article-title><source>Neurology</source><year>2009</year><volume>72</volume><fpage>1230</fpage><lpage>1235</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000345666.83318.03</pub-id><pub-id pub-id-type="pmid">19349602</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garg</surname><given-names>RK</given-names></name><name><surname>Liebling</surname><given-names>SM</given-names></name><name><surname>Maas</surname><given-names>MB</given-names></name><name><surname>Nemeth</surname><given-names>AJ</given-names></name><name><surname>Russell</surname><given-names>EJ</given-names></name><name><surname>Naidech</surname><given-names>AM</given-names></name></person-group><article-title>Blood pressure reduction, decreased diffusion on MRI, and outcomes after intracerebral hemorrhage</article-title><source>Stroke</source><year>2012</year><volume>43</volume><fpage>67</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1161/STROKEAHA.111.629493</pub-id><pub-id pub-id-type="pmid">21980211</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kothari</surname><given-names>RU</given-names></name><name><surname>Brott</surname><given-names>T</given-names></name><name><surname>Broderick</surname><given-names>JP</given-names></name><name><surname>Barsan</surname><given-names>WG</given-names></name><name><surname>Sauerbeck</surname><given-names>LR</given-names></name><name><surname>Zuccarello</surname><given-names>M</given-names></name><etal/></person-group><article-title>The ABCs of measuring intracerebral hemorrhage volumes</article-title><source>Stroke</source><year>1996</year><volume>27</volume><issue>8</issue><fpage>1304</fpage><lpage>1305</lpage><pub-id pub-id-type="doi">10.1161/01.STR.27.8.1304</pub-id><pub-id pub-id-type="pmid">8711791</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butcher</surname><given-names>K</given-names></name><name><surname>Laidlaw</surname><given-names>J</given-names></name></person-group><article-title>Current intracerebral haemorrhage management</article-title><source>J Clin Neurosci</source><year>2003</year><volume>10</volume><issue>2</issue><fpage>158</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1016/S0967-5868(02)00324-7</pub-id><pub-id pub-id-type="pmid">12637041</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prabhakaran</surname><given-names>S</given-names></name><name><surname>Naidech</surname><given-names>AM</given-names></name></person-group><article-title>Ischemic brain injury after intracerebral hemorrhage: a critical review</article-title><source>Stroke</source><year>2012</year><volume>43</volume><issue>8</issue><fpage>2258</fpage><lpage>2263</lpage><pub-id pub-id-type="doi">10.1161/STROKEAHA.112.655910</pub-id><pub-id pub-id-type="pmid">22821611</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singer</surname><given-names>OC</given-names></name><name><surname>Kurre</surname><given-names>W</given-names></name><name><surname>Humpich</surname><given-names>MC</given-names></name><name><surname>Lorenz</surname><given-names>MW</given-names></name><name><surname>Kastrup</surname><given-names>A</given-names></name><name><surname>Liebeskind</surname><given-names>DS</given-names></name><etal/></person-group><article-title>Risk assessment of symptomatic intracerebral hemorrhage after thrombolysis using DWI-Aspects</article-title><source>Stroke</source><year>2009</year><volume>40</volume><issue>8</issue><fpage>2743</fpage><lpage>2748</lpage><pub-id pub-id-type="doi">10.1161/STROKEAHA.109.550111</pub-id><pub-id pub-id-type="pmid">19498190</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Brazzelli M, Sandercock Peter AG, Chappell Francesca M, Celani Maria G, Righetti E, Arestis N, et al. Magnetic resonance imaging versus computed tomography for detection of acute vascular lesions in patients presenting with stroke symptoms. Cochrane Database Syst Rev. 2009; doi:10.1002/14651858.CD007424.pub2.</mixed-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butcher</surname><given-names>KS</given-names></name><name><surname>Baird</surname><given-names>T</given-names></name><name><surname>MacGregor</surname><given-names>L</given-names></name><name><surname>Desmond</surname><given-names>P</given-names></name><name><surname>Tress</surname><given-names>B</given-names></name><name><surname>Davis</surname><given-names>S</given-names></name></person-group><article-title>Perihematomal edema in primary intracerebral hemorrhage is plasma derived</article-title><source>Stroke</source><year>2004</year><volume>35</volume><issue>8</issue><fpage>1879</fpage><lpage>1885</lpage><pub-id pub-id-type="doi">10.1161/01.STR.0000131807.54742.1a</pub-id><pub-id pub-id-type="pmid">15178826</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murat Arsava</surname><given-names>E</given-names></name><name><surname>Kayim-Yildiz</surname><given-names>O</given-names></name><name><surname>Oguz</surname><given-names>KK</given-names></name><name><surname>Akpinar</surname><given-names>E</given-names></name><name><surname>Topcuoglu</surname><given-names>MA</given-names></name></person-group><article-title>Elevated Admission Blood Pressure and Acute Ischemic Lesions in Spontaneous Intracerebral Hemorrhage</article-title><source>J Stroke Cerebrovasc Dis</source><year>2013</year><volume>22</volume><issue>3</issue><fpage>250</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1016/j.jstrokecerebrovasdis.2011.08.006</pub-id><pub-id pub-id-type="pmid">21963218</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casaubon</surname><given-names>LK</given-names></name><name><surname>Boulanger</surname><given-names>J</given-names></name><name><surname>Blacquiere</surname><given-names>D</given-names></name><name><surname>Boucher</surname><given-names>S</given-names></name><name><surname>Brown</surname><given-names>K</given-names></name><name><surname>Goddard</surname><given-names>T</given-names></name><etal/></person-group><article-title>Canadian&#x02005;stroke&#x02005;best&#x02005;practice&#x02005;recommendations: hyperacute stroke care guidelines, update 2015</article-title><source>Int J Stroke</source><year>2015</year><volume>10</volume><issue>6</issue><fpage>924</fpage><lpage>940</lpage><pub-id pub-id-type="doi">10.1111/ijs.12551</pub-id><pub-id pub-id-type="pmid">26148019</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hemphill</surname><given-names>JC</given-names></name><name><surname>Greenberg</surname><given-names>SM</given-names></name><name><surname>Anderson</surname><given-names>CS</given-names></name><name><surname>Becker</surname><given-names>K</given-names></name><name><surname>Bendok</surname><given-names>BR</given-names></name><name><surname>Cushman</surname><given-names>M</given-names></name><etal/></person-group><article-title>Guidelines for the management of spontaneous intracerebral hemorrhage</article-title><source>Stroke</source><year>2015</year><volume>46</volume><issue>7</issue><fpage>2032</fpage><lpage>2060</lpage><pub-id pub-id-type="doi">10.1161/STR.0000000000000069</pub-id><pub-id pub-id-type="pmid">26022637</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Shaw L, Price C, Mclure S, Howel D, Mccoll E, Younger P, et al. Paramedic Initiated Lisinopril For Acute Stroke Treatment ( PIL-FAST ): results from the pilot randomised controlled trial. Emerg Med J. 2014;31(12)994&#x02013;9.</mixed-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Right</surname><given-names>T</given-names></name><name><surname>Ankolekar</surname><given-names>S</given-names></name><name><surname>Fuller</surname><given-names>M</given-names></name><name><surname>Cross</surname><given-names>I</given-names></name><name><surname>Renton</surname><given-names>C</given-names></name><name><surname>Cox</surname><given-names>P</given-names></name><etal/></person-group><article-title>Feasibility of an ambulance-based stroke trial, and safety of glyceryl trinitrate in ultra-acute stroke: the rapid intervention with glyceryl trinitrate in hypertensive stroke trial (RIGHT, ISRCTN66434824)</article-title><source>Stroke</source><year>2013</year><volume>44</volume><fpage>3120</fpage><lpage>3128</lpage><pub-id pub-id-type="doi">10.1161/STROKEAHA.113.001301</pub-id><pub-id pub-id-type="pmid">24003041</pub-id></element-citation></ref></ref-list></back></article>